{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:48:59Z","timestamp":1779108539108,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"South Dakota Bioscience Commercialization Alliance","award":["i6"],"award-info":[{"award-number":["i6"]}]},{"name":"The Shepherd Gift"},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DGE-1633213"],"award-info":[{"award-number":["DGE-1633213"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of South Dakota, Department of Biomedical Engineering"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Huntington disease (HD) is a neurodegenerative disease where a genetic mutation leads to excessive polyglutamine (Q) repeats in the huntingtin protein. The polyglutamine repeats create toxic plaques when the protein is cleaved, leading to neuron death. The glycolipid GM1 ganglioside (GM1) has been shown to be neuroprotective in HD models, as it prevents the cleavage of the mutant huntingtin protein by phosphorylation of serine 13 and 16. Previous studies have tested GM1 in both adult-onset and juvenile-onset HD models, but this study set out to investigate whether GM1 mediated cytoprotection is influenced by the length of polyglutamine repeats.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method and result<\/jats:title>\n                <jats:p>This study utilized cell culture to analyze the effect of GM1 on cell viability, directly comparing the response between cells with adult-onset HD and juvenile-onset HD. HEK293 cells expressing either wild-type huntingtin (Htt) (19Q) exon 1, adult-onset HD mutant Htt exon 1 (55Q), or Juvenile HD mutant Htt exon 1 (94Q) were assessed for cell viability using the WST-1 assay. Our results suggested moderate doses of GM1 increased cell viability for all cell lines when compared to untreated cells. When comparing HEK293 55Q and 94Q cells, there was no difference in cell viability within each dose of GM1.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These data suggest cellular responses to GM1 are independent of polyglutamine repeats in HD cells and provide insight on GM1\u2019s application as a therapeutic agent for HD and other diseases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11033-022-07830-2","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T16:02:54Z","timestamp":1664553774000},"page":"12253-12258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The cytoprotective role of GM1 ganglioside in Huntington disease cells"],"prefix":"10.1007","volume":"49","author":[{"given":"Hannah S.","family":"Hart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeline A.","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie Toering","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan W.","family":"Holler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron F.","family":"Harmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry D.","family":"Holler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"7830_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.5","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ (2015) Huntington disease. Nat Rev Dis Primers. https:\/\/doi.org\/10.1038\/nrdp.2015.5","journal-title":"Nat Rev Dis Primers"},{"key":"7830_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3389\/fnins.2016.00457","volume":"10","author":"A Di Pardo","year":"2016","unstructured":"Di Pardo A, Amico E, Maglione V (2016) Impaired levels of gangliosides in the corpus callosum of Huntington disease animal models. Front Neurosci 10:457. https:\/\/doi.org\/10.3389\/fnins.2016.00457","journal-title":"Front Neurosci"},{"key":"7830_CR3","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1523\/JNEUROSCI.6348-09.2010","volume":"30","author":"V Maglione","year":"2010","unstructured":"Maglione V, Marchi P, Di Pardo A, Lingrell S, Horkey M, Tidmarsh E, Sipione S (2010) Impaired ganglioside metabolism in Huntington\u2019s disease and neuroprotective role of GM1. J Neurosci 30:4072. https:\/\/doi.org\/10.1523\/JNEUROSCI.6348-09.2010","journal-title":"J Neurosci"},{"key":"7830_CR4","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.febslet.2009.12.010","volume":"584","author":"E Posse de Chaves","year":"2010","unstructured":"Posse de Chaves E, Sipione S (2010) Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS Lett 584:1748\u20131759. https:\/\/doi.org\/10.1016\/j.febslet.2009.12.010","journal-title":"FEBS Lett"},{"key":"7830_CR5","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00018-005-5188-y","volume":"62","author":"I Mocchetti","year":"2005","unstructured":"Mocchetti I (2005) Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell Mol Life Sci 62:2283\u20132294. https:\/\/doi.org\/10.1007\/s00018-005-5188-y","journal-title":"Cell Mol Life Sci"},{"key":"7830_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mcn.2008.09.007","volume":"40","author":"SC Warby","year":"2009","unstructured":"Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR (2009) Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 40:121\u2013127. https:\/\/doi.org\/10.1016\/j.mcn.2008.09.007","journal-title":"Mol Cell Neurosci"},{"key":"7830_CR7","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.neuron.2009.11.020","volume":"64","author":"X Gu","year":"2009","unstructured":"Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LM, Wetzel R, Yang XW (2009) Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64:828\u2013840. https:\/\/doi.org\/10.1016\/j.neuron.2009.11.020","journal-title":"Neuron"},{"key":"7830_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nchembio.582","volume":"7","author":"RS Atwal","year":"2011","unstructured":"Atwal RS, Desmond CR, Caron N, Maiuri T, Xia J, Sipione S, Truant R (2011) Kinase inhibitors modulate huntingtin cell localization and toxicity. Nat Chem Biol 7:453\u2013460. https:\/\/doi.org\/10.1038\/nchembio.582","journal-title":"Nat Chem Biol"},{"key":"7830_CR9","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1093\/hmg\/ddn281","volume":"17","author":"D Zala","year":"2008","unstructured":"Zala D, Colin E, Rangone H, Liot G, Humbert S, Saudou F (2008) Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 17:3837\u20133846. https:\/\/doi.org\/10.1093\/hmg\/ddn281","journal-title":"Hum Mol Genet"},{"key":"7830_CR10","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1073\/pnas.1114502109","volume":"109","author":"A Di Pardo","year":"2012","unstructured":"Di Pardo A, Maglione V, Alpaugh M, Horkey M, Atwal RS, Sassone J, Ciammola A, Steffan JS, Fouad K, Truant R, Sipione S (2012) Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc Natl Acad Sci 109:3528. https:\/\/doi.org\/10.1073\/pnas.1114502109","journal-title":"Proc Natl Acad Sci"},{"key":"7830_CR11","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.15252\/emmm.201707763","volume":"9","author":"M Alpaugh","year":"2017","unstructured":"Alpaugh M, Galleguillos D, Forero J, Morales LC, Lackey SW, Kar P, Di Pardo A, Holt A, Kerr BJ, Todd KG, Baker GB, Fouad K, Sipione S (2017) Disease-modifying effects of ganglioside GM1 in Huntington\u2019s disease models. EMBO Mol Med 9:1537\u20131557. https:\/\/doi.org\/10.15252\/emmm.201707763","journal-title":"EMBO Mol Med"},{"key":"7830_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1074\/jbc.M111.294280","volume":"287","author":"G Dong","year":"2012","unstructured":"Dong G, Callegari EA, Gloeckner CJ, Ueffing M, Wang H (2012) Prothymosin-alpha interacts with mutant huntingtin and suppresses its cytotoxicity in cell culture. J Biol Chem 287:1279\u20131289. https:\/\/doi.org\/10.1074\/jbc.M111.294280","journal-title":"J Biol Chem"},{"key":"7830_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nsmb.1570","volume":"16","author":"AK Thakur","year":"2009","unstructured":"Thakur AK, Jayaraman M, Mishra R, Thakur M, Chellgren VM, Byeon IJ, Anjum DH, Kodali R, Creamer TP, Conway JF, Gronenborn AM, Wetzel R (2009) Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol 16:380\u2013389. https:\/\/doi.org\/10.1038\/nsmb.1570","journal-title":"Nat Struct Mol Biol"},{"key":"7830_CR14","doi-asserted-by":"publisher","first-page":"e0155747","DOI":"10.1371\/journal.pone.0155747","volume":"11","author":"B Sahoo","year":"2016","unstructured":"Sahoo B, Arduini I, Drombosky KW, Kodali R, Sanders LH, Greenamyre JT, Wetzel R (2016) Folding landscape of mutant Huntingtin Exon1: diffusible multimers, oligomers and fibrils, and no detectable monomer. PLoS ONE 11:e0155747. https:\/\/doi.org\/10.1371\/journal.pone.0155747","journal-title":"PLoS ONE"},{"key":"7830_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3389\/fneur.2019.00859","volume":"10","author":"PJ Magistretti","year":"2019","unstructured":"Magistretti PJ, Geisler FH, Schneider JS, Li PA, Fiumelli H, Sipione S (2019) Gangliosides: treatment avenues in neurodegenerative disease. Front Neurol 10:859. https:\/\/doi.org\/10.3389\/fneur.2019.00859","journal-title":"Front Neurol"},{"key":"7830_CR16","doi-asserted-by":"publisher","first-page":"572965","DOI":"10.3389\/fnins.2020.572965","volume":"14","author":"S Sipione","year":"2020","unstructured":"Sipione S, Monyror J, Galleguillos D, Steinberg N, Kadam V (2020) Gangliosides in the brain: physiology, pathophysiology and therapeutic applications. Front Neurosci 14:572965. https:\/\/doi.org\/10.3389\/fnins.2020.572965","journal-title":"Front Neurosci"},{"key":"7830_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21030868","author":"E Chiricozzi","year":"2020","unstructured":"Chiricozzi E, Lunghi G, Di Biase E, Fazzari M, Sonnino S, Mauri L (2020) GM1 ganglioside is a key factor in maintaining the mammalian neuronal functions avoiding neurodegeneration. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21030868","journal-title":"Int J Mol Sci"},{"key":"7830_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.tibs.2015.04.005","volume":"40","author":"RW Ledeen","year":"2015","unstructured":"Ledeen RW, Wu G (2015) The multi-tasked life of GM1 ganglioside, a true factotum of nature. Trends Biochem Sci 40:407\u2013418. https:\/\/doi.org\/10.1016\/j.tibs.2015.04.005","journal-title":"Trends Biochem Sci"},{"key":"7830_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1023\/a:1020209008169","volume":"7\u20138","author":"T Mutoh","year":"2002","unstructured":"Mutoh T, Hamano T, Yano S, Koga H, Yamamoto H, Furukawa K, Ledeen RW (2002) Stable transfection of GM1 synthase gene into GM1-deficient NG108-15 cells, CR-72 cells, rescues the responsiveness of Trk-neurotrophin receptor to its ligand, NGF. Neurochem Res 7\u20138:801\u2013806. https:\/\/doi.org\/10.1023\/a:1020209008169","journal-title":"Neurochem Res"},{"key":"7830_CR20","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.neuropharm.2010.10.012","volume":"60","author":"ST Lim","year":"2011","unstructured":"Lim ST, Esfahani K, Avdoshina V, Mocchetti I (2011) Exogenous gangliosides increase the release of brain-derived neurotrophic factor. Neuropharmacology 60:1160\u20131167. https:\/\/doi.org\/10.1016\/j.neuropharm.2010.10.012","journal-title":"Neuropharmacology"},{"key":"7830_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.04.975862","author":"D Galleguillos","year":"2020","unstructured":"Galleguillos D, Wang Q, Steinberg N, Shrivastava G, Dhami K, Rubinstein K, Giuliani F, Churchward M, Power C, Todd K, Sipione S (2020) Anti-inflammatory role of GM1 and modulatory effects of gangliosides on microglia functions. bioRxiv. https:\/\/doi.org\/10.1101\/2020.03.04.975862","journal-title":"bioRxiv"},{"key":"7830_CR22","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","volume":"89","author":"F Saudou","year":"2016","unstructured":"Saudou F, Humbert S (2016) The biology of Huntingtin. Neuron 89:910\u2013926. https:\/\/doi.org\/10.1016\/j.neuron.2016.02.003","journal-title":"Neuron"},{"key":"7830_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jns.2010.02.009","volume":"292","author":"JS Schneider","year":"2010","unstructured":"Schneider JS, Sendek S, Daskalakis C, Cambi F (2010) GM1 ganglioside in Parkinson\u2019s disease: results of a five year open study. J Neurol Sci 292:45\u201351. https:\/\/doi.org\/10.1016\/j.jns.2010.02.009","journal-title":"J Neurol Sci"},{"key":"7830_CR24","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1097\/00007632-200112151-00015","volume":"26S","author":"FH Geisler","year":"2001","unstructured":"Geisler FH, Coleman WP, Grieco G, Poonian D (2001) The Sygen\u00ae multicenter acute spinal cord injury study. Spine 26S:S87-98","journal-title":"Spine"},{"key":"7830_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1749-6632.1998.tb09691.x","volume":"845","author":"M Alter","year":"1998","unstructured":"Alter M (1998) GM1 ganglioside for acute ischemic stroke: trial design issues. Ann N Y Acad Sci 845:391\u2013401. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb09691.x","journal-title":"Ann N Y Acad Sci"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07830-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-07830-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07830-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T19:50:34Z","timestamp":1669837834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-07830-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7830"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-07830-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}